Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CLSD

Clearside Biomedical Inc

Dec 10 • 04:00PM ET

1.00

Dollar change -0.02
Percentage change -1.96	%

Healthcare • Biotechnology • USA • NASD

Peers: EYPT VKTX OCUL CARA ALDX RIGL IRD AKBA BYSI

| Held by: VTI VXF IWC EVNT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.45	Insider Own	15.52%	Shs Outstand	74.75M	Perf Week	-7.41%
Market Cap	75.84M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	0.51%	Shs Float	64.07M	Perf Month	-12.28%
Income	-31.88M	PEG	-	EPS next Q	-0.10	Inst Own	15.97%	Short Float	2.08%	Perf Quarter	-23.66%
Sales	7.70M	P/S	9.85	EPS this Y	11.86%	Inst Trans	-18.74%	Short Ratio	1.82	Perf Half Y	-20.00%
Book/sh	-0.47	P/B	-	EPS next Y	3.67%	ROA	-100.27%	Short Interest	1.34M	Perf Year	-8.26%
Cash/sh	0.31	P/C	3.21	EPS next 5Y	-	ROE	-1310.02%	52W Range	0.92 - 2.12	Perf YTD	-14.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.88%	ROI	-215.23%	52W High	-52.83%	Beta	2.20
Dividend TTM	-	Quick Ratio	4.49	Sales past 5Y	1621.13%	Gross Margin	97.83%	52W Low	8.70%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	4.49	EPS Y/Y TTM	26.05%	Oper. Margin	-319.98%	RSI (14)	40.71	Volatility	6.20% 5.84%
Employees	30	Debt/Eq	-	Sales Y/Y TTM	248.39%	Profit Margin	-413.83%	Recom	1.00	Target Price	6.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	31.17%	Payout	-	Rel Volume	0.32	Prev Close	1.02
Sales Surprise	698.46%	EPS Surprise	19.55%	Sales Q/Q	20.84%	Earnings	Nov 12 AMC	Avg Volume	733.82K	Price	1.00
SMA20	-4.72%	SMA50	-11.79%	SMA200	-19.20%	Trades		Volume	237,789	Change	-1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-24	Initiated	Chardan Capital Markets	Buy	$6
Jun-25-24	Initiated	Oppenheimer	Outperform	$5
Dec-15-21	Resumed	Wedbush	Outperform	$19 → $9
Jul-29-21	Initiated	H.C. Wainwright	Buy	$10
May-13-20	Initiated	ROTH Capital	Buy	$8
Aug-09-19	Downgrade	Needham	Buy → Hold
Nov-05-18	Downgrade	Stifel	Buy → Hold
Nov-05-18	Downgrade	JP Morgan	Overweight → Underweight
Nov-05-18	Downgrade	Cowen	Outperform → Market Perform
Mar-06-18	Reiterated	Needham	Buy	$18 → $22
May-25-17	Initiated	JMP Securities	Mkt Outperform	$21
Feb-24-17	Initiated	JP Morgan	Overweight	$19
Nov-10-16	Reiterated	Needham	Buy	$16 → $24
Oct-24-16	Reiterated	Stifel	Buy	$13 → $23

Show Previous Ratings

Nov-25-24 07:05AM	Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States (GlobeNewswire)
Nov-15-24 12:00PM	All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy (Zacks) -5.71%
Nov-13-24 02:17AM	Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Call Highlights: Promising Clinical Trial ... (GuruFocus.com)
Nov-12-24 06:05PM	Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:23AM	Loading…
Nov-11-24 07:23AM	Clearside Biomedical Inc (CLSD) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-08-24 03:56AM	Santen, Arctic Vision sign deal for ARVN001 to treat UME (Pharmaceutical Technology)
Nov-07-24 09:05AM	Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Nov-06-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:05AM	Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors (GlobeNewswire)
Oct-31-24 07:05AM	Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-22-24 07:05AM	Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting (GlobeNewswire) -10.23%
Oct-10-24 08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-09-24 10:22AM	Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study (Benzinga) -11.49%
06:30AM	Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes (GlobeNewswire)
07:05AM	Loading…
Aug-27-24 07:05AM	Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Aug-15-24 09:35AM	After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD) (Zacks)
Aug-12-24 05:25PM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-24 07:05AM	Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-05-24 10:00AM	Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Aug-01-24 07:05AM	Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 (GlobeNewswire)
Jul-29-24 04:05PM	Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS for Suprachoroidal Use in Uveitic Macular Edema Patients in China (GlobeNewswire)
Jul-22-24 12:00PM	Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET (GlobeNewswire)
Jul-11-24 07:05AM	Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board (GlobeNewswire)
Jun-27-24 07:05AM	Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery (GlobeNewswire) +5.79%
Jun-12-24 07:05AM	Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting (GlobeNewswire)
May-21-24 07:05AM	Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS ) Injection in Leading Peer-Reviewed Industry Journal, RETINA (GlobeNewswire) +12.03%
May-13-24 08:20AM	HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating (MT Newswires)
May-10-24 02:15PM	Q1 2024 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents) -7.41%
11:56AM	Loading…
11:56AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:55PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +6.30%
04:05PM	Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 04:15PM	Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-30-24 07:05AM	Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-16-24 07:05AM	Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors (GlobeNewswire) -10.85%
Apr-02-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -11.39%
Mar-18-24 07:05AM	Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer (GlobeNewswire) -8.77%
Mar-13-24 08:30AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:38AM	Q4 2023 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 05:35PM	Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ... (GuruFocus.com) -18.81%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 02:25PM	These 2 Strong Buy Penny Stocks Could Surge Over 200%, Say Analysts (TipRanks) +8.63%
Feb-29-24 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 (GlobeNewswire)
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-07-24 08:00AM	Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering (GlobeNewswire)
Dec-14-23 07:05AM	Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Nov-14-23 09:11AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:05PM	Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-23 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference (GlobeNewswire) -9.65%
Nov-07-23 04:20PM	Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector (GlobeNewswire) +19.39%
Nov-02-23 07:05AM	Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Nov-01-23 07:05AM	Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD (GlobeNewswire) +5.30%
Oct-31-23 07:05AM	Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023 (GlobeNewswire) +5.17%
Oct-26-23 12:24AM	3 Cheap Stocks to Buy Under $1 in October 2023 (InvestorPlace) -5.28%
Oct-16-23 07:05AM	Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 09:00AM	Clearside Biomedical Announces Advancement of XIPERE in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China (GlobeNewswire)
Oct-03-23 04:35PM	Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit (GlobeNewswire)
Sep-19-23 07:05AM	Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-14-23 04:05PM	Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.60%
Aug-02-23 04:30PM	Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023 (GlobeNewswire) -5.26%
Aug-01-23 07:05AM	Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023 (GlobeNewswire)
Jul-31-23 07:05AM	Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting (GlobeNewswire)
Jul-20-23 07:05AM	Clearside Biomedicals Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings (GlobeNewswire)
Jul-11-23 04:05PM	Clearside Biomedical CEO George Lasezkay to Present at the SHARE Series Investor Event on Monday, July 17, 2023 (GlobeNewswire)
Jul-10-23 07:05AM	Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Jun-29-23 09:50AM	We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate (Simply Wall St.)
Jun-01-23 07:05AM	Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
May-11-23 08:25AM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.90%
07:05AM	Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:30PM	Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%
May-02-23 07:05AM	Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023 (GlobeNewswire)
Apr-27-23 07:05AM	Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting (GlobeNewswire)
Apr-18-23 07:05AM	Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
Apr-12-23 07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.48%
Apr-09-23 09:42AM	Clearside Biomedical (NASDAQ:CLSD) adds US$12m to market cap in the past 7 days, though investors from five years ago are still down 88% (Simply Wall St.)
Apr-05-23 07:05AM	Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians (GlobeNewswire) -8.89%
Mar-11-23 03:14AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 06:35PM	Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.24%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-23 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023 (GlobeNewswire) -5.26%
Feb-21-23 07:05AM	Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings (GlobeNewswire)
Feb-07-23 07:05AM	Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023 (GlobeNewswire)
Feb-06-23 07:30AM	Clearside Biomedical Announces Leadership Team Update (GlobeNewswire)
Feb-02-23 01:18PM	Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder (Benzinga)
07:05AM	Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
Dec-22-22 09:52AM	2 Strong Buy Penny Stocks That Could Go Boom (TipRanks) +8.00%
05:05AM	Companies Like Clearside Biomedical (NASDAQ:CLSD) Can Afford To Invest In Growth (Simply Wall St.)
Nov-22-22 07:05AM	Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022 (GlobeNewswire)
Nov-11-22 05:26AM	Clearside Biomedical Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 01:24PM	Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data (Benzinga)
07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference (GlobeNewswire)
Nov-09-22 09:05AM	Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.57%
07:15AM	Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
07:05AM	Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients (GlobeNewswire)
Nov-08-22 04:05PM	Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 07:05AM	Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022 (GlobeNewswire) +11.57%
Oct-31-22 08:52AM	Investors in Clearside Biomedical (NASDAQ:CLSD) have unfortunately lost 84% over the last five years (Simply Wall St.)
Oct-17-22 11:27AM	Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chong Ngai Hang Victor	Chief Medical Officer	Nov 01 '24	Buy	1.00	36,500	36,500	100,000	Nov 04 04:15 PM
Chong Ngai Hang Victor	Chief Medical Officer	Jun 24 '24	Buy	1.06	23,500	24,910	63,500	Jun 24 04:38 PM
YERXA BENJAMIN R	Director	May 15 '24	Buy	1.31	7,813	10,235	17,957	May 15 05:28 PM
Gibney Anthony S	Director	Apr 18 '24	Buy	1.30	93,290	121,277	100,000	Apr 19 09:45 AM
Gibney Anthony S	Director	Apr 17 '24	Buy	1.25	6,710	8,388	6,710	Apr 19 09:45 AM
Chong Ngai Hang Victor	CHIEF MEDICAL OFFICER	Mar 20 '24	Buy	1.60	30,000	48,000	30,000	Mar 20 04:30 PM
WHITMORE BRADFORD T	10% Owner	Feb 07 '24	Buy	1.35	444,444	599,999	4,495,034	Feb 09 01:00 PM
LASEZKAY GEORGE M	CEO	Jan 19 '24	Sale	1.27	18,000	22,860	466,577	Jan 19 06:26 PM
Deignan Charles A.	Chief Financial Officer	Jan 19 '24	Sale	1.28	12,900	16,512	384,662	Jan 19 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLSD

Clearside Biomedical Inc

Upgrade your FINVIZ experience